Inmunoterapia en Primera Linea. Avanzando en el tratamiento del CPNM

13 / 42

13
ORR by Tumor Mutation Burden Subgroup
CheckMate 026 TMB Analysis: Nivolumab in First-line NSCLC
111 94 47 60 n =
47
23
28 33
0
10
20
30
40
50
60
70
80
90
100
High Low/medium
ORR (%)
TMB Subgroup
Nivolumab
Chemotherapy